SCHEMBL7446183

SCHEMBL7446183

CCOC(=O)c1cccnc1Nc1cccc(C(=O)OC(C)C)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 4/20 0.55
▸ SMN1; SMN2 Q16637 5/20 0.53
▸ RAB9A P51151 4/20 0.53
▸ NPC1 O15118 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ MAPT P10636 6/20 0.51
▸ LMNA P02545 3/20 0.51
▸ POLB P06746 2/20 0.51
▸ HPGD P15428 3/20 0.50
▸ PKM P14618 2/20 0.49
▸ PPIA P62937 1/20 0.48
▸ TP53 P04637 3/20 0.48
▸ BRAF P15056 1/20 0.48
▸ ALOX15 P16050 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ KDR P35968 1/20 0.47
▸ MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26742261 0.83 HTT (0.56) HTTSMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL11833609 0.80 HTT (0.68) HTTSMN1; SMN2RAB9ANPC1MAPT
SCHEMBL7440301 0.79 MEN1 (0.60) HTTSMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL6797722 0.79 CDC25B (0.63) HTTSMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL8693048 0.78 ELANE (0.52) HTTSMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL8689929 0.78 LMNA (0.69) HTTSMN1; SMN2KDM4EMAPTLMNA
SCHEMBL11790155 0.77 KMT2A (0.69) HTTSMN1; SMN2RAB9ANPC1MAPT
SCHEMBL10378109 0.77 HTT (0.54) HTTSMN1; SMN2RAB9ANPC1MAPT
SCHEMBL11830768 0.76 DHODH (0.56) HTTSMN1; SMN2RAB9ANPC1MAPT
SCHEMBL6797565 0.75 MAPT (0.78) HTTSMN1; SMN2RAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6037345-A Method for inhibiting neoplastic cells and related conditions by exposure to quinazolinedione and pyridopyrimidinedione derivatives CELL PATHWAYS, INC. (US) 2000-03-14 — — US disclosed
EP-0260817-B1 QUINAZOLINEDIONES AND PYRIDOPYRIMIDINEDIONES PFIZER INC. (US) 1991-05-15 — — EP disclosed
US-4880810-A Quinazolinediones and pyridopyrimidinediones PFIZER INC. (US) 1989-11-14 — — US disclosed
US-4797403-A Quinazolinediones and pyridopyrimidinediones PFIZER INC. (US) 1989-01-10 — — US disclosed
EP-0260817-A1 Quinazolinediones and pyridopyrimidinediones PFIZER INC. (US) 1988-03-23 — — EP disclosed
WO-1988001270-A1 PYRIDOPYRIMIDINEDIONES PFIZER INC. (US) 1988-02-25 — — WO disclosed
Send feedback